Santa’s first delivery of the season has arrived 🎅 🎄 🎁 , with official acceptance and publication of our paper on [3+2] alkene (hetero)annulation in Nat. Commun. The project was carried out in collaboration with the Liu group at the University of Pittsburgh and the chemists from the Oncology Medicinal Chemistry Department at Pfizer, Inc. By taking advantage of a unique Pd(II)/Pd(IV) pathway that begins with directed nucleopalladation, this transformation conveniently furnishes indolines, dihydrobenzofurans, and indanes with trans stereochemistry across the ring juncture. The practicality of the method stems from its use of readily available alkenyl amide substrates and ambiphilic aryl halide coupling partners. Bravo to Hui-Qi, Pranali, Andrew, and Hou-Xiang from our lab, Ilia from the Liu lab, and Joyann, Shouliang, Michelle, and Indra from Pfizer.
Click here for a link to the paper: https://www.nature.com/articles/s41467-020-20182-4
The work first appeared as pre-print back in June: https://chemrxiv.org/articles/preprint/Anti-Selective_3_2_Hetero_annulation_of_Non-Conjugated_Alkenes_via_Directed_Nucleopalladation/12510038